Tang Jinhai

 

CURRICULUM VITAE
 Tang Jinhai
 
1. Personal Information
Title/Position:
Correspondence Address:
Telephone:
Fax:
E-mail:
 
2. Education
DEGREE
(if applicable)
MM/YY
FIELD OF STUDY
Xuzhou medical college, Xuzhou, China
B.S.
07/83
Clinical medicine
Nanjing university of Chinese medicine, Nanjing, China
Ph.D.
07/08
Clinical medicine
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Research Interests
I am currently concentrating on the clinic diagnose and research of breast tumor. I major in diagnosis, therapy and screening and iidentification of prognostic tumor markers in breast cancer and provide a large number of basic and clinical applications for breast cancer prevention and treatment individualized. I carried out a study of tumor susceptibility genes associated with breast cancer relationship, screened 12 genes related to cancer treatment that can forecast breast cancer recurrence and metastasis expression profiling by molecular epidemiological studies, developed the method of detection for circulating tumor cells in peripheral blood and found a number of cytokines associated with breast cancer recurrence and metastasis by the application of cell biology techniques; explored the mechanisms of HAP1 gene's role in the development of breast cancer by the application of gene knockout and transfection technology in cytological experiments and animal studies; proposed some new molecular targets that may related with diagnosis, treatment and new drug development in the research of drug resistance genes. Currently, I preside the National Natural Science Foundation of China about “Study on the role of intercellular miRNA tranfer by microvesicles in drug resistance of breast cancer and its molecular mechanism”, mainly investigate miRNA and the course of conduct and characteristic of the delivery of breast cancer drug resistance and study the system of transduction molecules. This study aims to clarify one kind of brand new drug resistance mechanisms and provide a new therapeutic approach for the clinical treatment of refractory tumors.
 
4. Selected Publications
(1) Li XJ, Ji MH, Zhong SL, Zha QB, Xu JJ, Zhao JH, Tang JH. MicroRNA-34a Modulates Chemosensitivity of Breast Cancer Cells to Adriamycin by Targeting Notch1. Arch Med Res. 2012 Oct 16. pii: S0188-4409(12)00276-7. doi: 10.1016/j.arcmed.2012.09.007. [Epub ahead of print]
 
(2) Jiang AR, Gao CM, Ding JH, Li SP, Liu YT, Cao HX, Wu JZ, Tang JH, Qian Y, Tajima K.. Abortions and breast cancer risk in premenopausal and postmenopausal women in Jiangsu Province of China.. Asian Pac J Cancer Prev. 2012;13(1):33-5.
 
(3) Huang XE, Li CG, Li Y, Lu YY, Tang JH, Xiang J. Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial. Asian Pac J Cancer Prev. 2011;12(10):2797-800.
 
(4) Xu HX, Huang XE, Li Y, Li CG, Tang JH. A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev. 2011;12(9):2233-6.
 
(5) Li Y, Tang JH, Huang XE, Li CG. Clinical comparison on the safety and efficacy of fluorouracil/pirarubicin/cyclophosphamide (FPC) with fluorouracil/ epirubicin/cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev. 2011;12(7):1795-8.
 
(6) Liu YT, Gao CM, Ding JH, Li SP, Cao HX, Wu JZ, Tang JH, Qian Y, Tajima K. Physiological, reproductive factors and breast cancer risk in Jiangsu province of China. Asian Pac J Cancer Prev. 2011;12(3):787-90.
 
(7) Gao LL, Huang XE, Zhang Q, Tang JH. A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev. 2011;12(1):77-80.
 
(8) Yan PW, Huang XE, Jiang Y, Tang JH, Xu HX, Xu X, Jin X. Clinical comparison of safety and efficacy of vinorelbine/epirubicin (NE) with fluorouracil/epirubicin/cyclophosphamide (FEC). Asian Pac J Cancer Prev. 2010;11(4):1115-8.
 
(9) Jiang Y, Huang XE, Yan PW, Cui L, Tang JH, Xiang J. Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev. 2010;11(4):1059-62.
 
(10) Yao CY, Huang XE, Tang JH, Xu HX. Clinical observations on safety of fixed dose rate gemcitabine chemotherapy by intravenous infusion. Asian Pac J Cancer Prev. 2010;11(2):553-5.
 
(11) Tang JH, Zhao JH, Lu JW, Yan F, Qin JW, Xu B. Circulating levels of angiogenic cytokines in advanced breast cancer patients with system chemotherapy and their potential value in monitoring disease course. J Cancer Res Clin Oncol. 2011 Jan;137(1):55-63. Epub 2010 Mar 10.
 
(12) Gao CM, Tajima K, Ding JH, Tang JH, Wu JZ, Li SP, Cao HX, Liu YT, Su P, Qian Y, Chang J, Takezaki T. Body size, physical activity and risk of breast cancer - a case control study in Jangsu Province of China. Asian Pac J Cancer Prev. 2009;10(5):877-81.
 
(13) Yao CY, Huang XE, Li C, Shen HB, Shi MQ, Feng JF, Pan LX, Tang JH. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. Asian Pac J Cancer Prev. 2009;10(5):859-64.
 
(14) Gao CM, Kazuo T, Tang JH, Cao HX, Ding JH, Wu JZ, Wang J, Liu YT, Li SP, Su P, Keitaro M, Toshiro T. [MTHFR polymorphisms, dietary folate intake and risks to breast cancer].[Article in Chinese] Zhonghua Yu Fang Yi Xue Za Zhi. 2009 Jul;43(7):576-80.
 
(15) Tang JH, Xu XM, Zheng KE, Qin JW, Zhao XS, Zhang T. [Lesion localization and surgical resection for non-palpable breast cancer].[Article in Chinese] Zhonghua Zhong Liu Za Zhi. 2009 Apr;31(4):305-7.
 
(16) Gao CM, Tang JH, Cao HX, Ding JH, Wu JZ, Wang J, Liu YT, Li SP, Su P, Matsuo K, Takezaki T, Tajima K. MTHFR polymorphisms, dietary folate intake and breast cancer risk in Chinese women. J Hum Genet. 2009 Jul;54(7):414-8. Epub 2009 Jun 26.
 
(17)Tang JH, Zhao JH, Wu JZ, Lu JW, Pan LQ, Xu ZY. [Establishment of a multiplex ligation-dependent SNP genotyping method and its application in the detection of genes related to chemotherapeutic drugs in breast cancer].[Article in Chinese] Zhonghua Zhong Liu Za Zhi. 2009 Feb;31(2):108-13.
 
 
5. Scholarly and Professional Activities
Vice chairman, Chinese medical doctor association (CMDA) Mammary gland committee of experts
Member, China anti-cancer association Mammary gland professional committee
Member, Chinese society of clinical oncology (CSCO) Executive committee
Member, Oncology branch committee of Chinese medical association
Vice director, Anti-cancer association council in Jiangsu province
Executive director, Jiangsu province medical association council
Chairman, the committee of Jiangsu province medical oncology branch
Chairman, the committee of Jiangsu anti-cancer association professional committee of breast cancer
Executive member, the council of Combination of traditional Chinese and western medicine in Jiangsu province to the council
Chairman, the committee of Professional committee of breast disease
Member, Jiangsu province medical association surgery branch
Member, The ministry of health of city, county hospital common tumor standardization committee of experts on the diagnosis and treatment
Editor in chief, China Surgical Oncology Magazine
Editor, China Endocrine Surgery Magazine, China's General External Basis and Clinical Magazine, Practical Clinical Medicine Magazine